Shu-Lin Liu

Shu-Lin Liu has worked in various roles since 2001. Shu-Lin began as a Research Assistant at National Cheng-Kung University (Transgenic Animal Model Core, Laboratory Animal Center), where they performed pronuclear microinjection and created several transgenic mice lines. Shu-Lin then worked as a Post-Doctoral Fellow at National Cheng-Kung University (Cardiovascular Research Center) from 2007 to 2009. From 2009 to 2018, they worked as a Postdoctoral Researcher at the University of Pennsylvania, where they identified and validated MMP12 as a therapeutic target in vascular injury and aging, and discovered a novel function of apoE-HDL in inhibiting ECM gene expression and arterial stiffening in atherosclerosis. From 2018 to 2020, they worked as a Scientist at Decibel Therapeutics, and from 2020 to 2021, they worked as a Senior Scientist at Biocytogen, where they were the study director for various external disease model projects. Currently, they are working as an Associate Director of in Vivo Pharmacology at Vesigen Therapeutics, Inc.

Shu-Lin Liu received their Master's degree in Biotechnology/Animal Science from National Chung Hsing University between 1998 and 2000. Shu-Lin then went on to obtain their Ph.D in Biochemistry/Cardiovascular Biology from National Cheng Kung University between 2002 and 2006. In 2016 and 2017, Shu-Lin Liu completed the Clinical Research Certificate Program (4 months) at Boston College.